Cargando…

Oncogenic roles of PRL-3 in FLT3-ITD induced acute myeloid leukaemia

FLT3-ITD mutations are prevalent mutations in acute myeloid leukaemia (AML). PRL-3, a metastasis-associated phosphatase, is a downstream target of FLT3-ITD. This study investigates the regulation and function of PRL-3 in leukaemia cell lines and AML patients associated with FLT3-ITD mutations. PRL-3...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jung Eun, Yuen, Hiu Fung, Zhou, Jian Biao, Al-aidaroos, Abdul Qader O, Guo, Ke, Valk, Peter J, Zhang, Shu Dong, Chng, Wee Joo, Hong, Cheng William, Mills, Ken, Zeng, Qi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3799491/ https://www.ncbi.nlm.nih.gov/pubmed/23929599 http://dx.doi.org/10.1002/emmm.201202183

Ejemplares similares

Independent oncogenic and therapeutic significance of phosphatase PRL-3 in FLT3-ITD–negative acute myeloid leukemia
por: Qu, Shuang, et al.
Publicado: (2014)

FLT3‐ITD mutations in acute myeloid leukaemia – molecular characteristics, distribution and numerical variation
por: Engen, Caroline, et al.
Publicado: (2021)

PRL-3 activates mTORC1 in Cancer Progression
por: Ye, Zu, et al.
Publicado: (2015)

PRL-3, a Metastasis Associated Tyrosine Phosphatase, Is Involved in FLT3-ITD Signaling and Implicated in Anti-AML Therapy
por: Zhou, Jianbiao, et al.
Publicado: (2011)

Flt3-ITD mutations in a mouse model of radiation-induced acute myeloid leukaemia
por: Finnon, R, et al.
Publicado: (2012)

Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia
por: Heydt, Q, et al.
Publicado: (2018)

FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia
por: Sorcini, D, et al.
Publicado: (2023)

Feature genes predicting the FLT3/ITD mutation in acute myeloid leukemia
por: LI, CHENGLONG, et al.
Publicado: (2016)

Clinico-Haematologic association and prognostic relevance of NPM1 and FLT3-ITD mutations in acute Myeloid Leukaemia
por: Mahmood, Rafia, et al.
Publicado: (2019)

PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021)

Arsenic trioxide induces autophagic degradation of the FLT3-ITD mutated protein in FLT3-ITD acute myeloid leukemia cells
por: Liu, Xiao-Jian, et al.
Publicado: (2020)

PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2019)

Author Correction: PRL3 induces polyploid giant cancer cells eliminated by PRL3-zumab to reduce tumor relapse
por: Thura, Min, et al.
Publicado: (2021)

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports
por: Martínez-Cuadrón, David, et al.
Publicado: (2020)

Author Correction: PRL3-zumab as an immunotherapy to inhibit tumors expressing PRL3 oncoprotein
por: Thura, Min, et al.
Publicado: (2021)

Engineering the First Chimeric Antibody in Targeting Intracellular PRL-3 Oncoprotein for Cancer Therapy in Mice
por: Guo, Ke, et al.
Publicado: (2012)

Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia
por: Burchert, Andreas
Publicado: (2021)

MicroRNA networks in FLT3-ITD acute myeloid leukemia
por: Hoang, Dinh Hoa, et al.
Publicado: (2022)

A novel combination regimen of BET and FLT3 inhibition for FLT3-ITD acute myeloid leukemia
por: Lee, Lauren Y., et al.
Publicado: (2021)

Autophagy activation mediates resistance to FLT3 inhibitors in acute myeloid leukemia with FLT3-ITD mutation
por: Xu, Dan, et al.
Publicado: (2022)

Gilteritinib as treatment for extra-medullary relapse of FLT3-ITD acute myeloid leukemia FLT3-ITD, after allogeneic haematopoietic stem cell transplantation
por: Iannotta, R., et al.
Publicado: (2022)

How ITD Insertion Sites Orchestrate the Biology and Disease of FLT3-ITD-Mutated Acute Myeloid Leukemia
por: Haage, Tobias R., et al.
Publicado: (2023)

Selective FLT3 inhibition of FLT3-ITD(+) acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns
por: Moore, Andrew S., et al.
Publicado: (2012)

getITD for FLT3-ITD-based MRD monitoring in AML
por: Blätte, Tamara J., et al.
Publicado: (2019)

The Src family kinase LCK cooperates with oncogenic FLT3/ITD in cellular transformation
por: Marhäll, Alissa, et al.
Publicado: (2017)

Targeting BTK for the treatment of FLT3-ITD mutated acute myeloid leukemia
por: Pillinger, Genevra, et al.
Publicado: (2015)

Gab2 is Essential for Transformation by FLT3-ITD in Acute Myeloid Leukemia
por: Sies, Katharina, et al.
Publicado: (2019)

Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia
por: Green, Alexa S., et al.
Publicado: (2015)

Combined inhibition of Notch and FLT3 produces synergistic cytotoxic effects in FLT3/ITD(+) acute myeloid leukemia
por: Li, Dan, et al.
Publicado: (2020)

Outcomes of pediatric acute myeloid leukemia patients with FLT3-ITD mutations in the pre-FLT3 inhibitor era
por: Choi, Sujin, et al.
Publicado: (2020)

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016)

Follistatin is a novel therapeutic target and biomarker in FLT3/ITD acute myeloid leukemia
por: He, Bai‐Liang, et al.
Publicado: (2020)

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells
por: Liu, Hao, et al.
Publicado: (2013)

Tyrosine 842 in the activation loop is required for full transformation by the oncogenic mutant FLT3-ITD
por: Kazi, Julhash U., et al.
Publicado: (2017)

Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation
por: Bogdanov, Konstantin, et al.
Publicado: (2023)

Distinct Metabolic features differentiating FLT3-ITD AML from FLT3-WT childhood Acute Myeloid Leukemia
por: Stockard, Bradley, et al.
Publicado: (2018)

Novel AXL-targeted agents overcome FLT3 inhibitor resistance in FLT3-ITD(+) acute myeloid leukemia cells
por: Liu, Yi, et al.
Publicado: (2021)

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia
por: Wang, Aoli, et al.
Publicado: (2020)

The combination effect of homoharringtonine and ibrutinib on FLT3-ITD mutant acute myeloid leukemia
por: Li, Xia, et al.
Publicado: (2017)

NPM1 and FLT3-ITD/TKD Gene Mutations in Acute Myeloid Leukemia
por: Naseem, Shano, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_daqqbpiejovm94fuvgc2ng3el1